Please login to the form below

Not currently logged in
Email:
Password:

Cubicin

This page shows the latest Cubicin news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Teva's generic version of Astellas' Advagraf

CHMP recommends Teva's generic version of Astellas' Advagraf

Meanwhile, Merck Sharp &Dohme ( MSD) also received an extension recommendation for Cubicin (daptomycin), an injectable antibiotic for adults and paediatric patients with staphylococcus aureus bacteraemia (SAB).

Latest news

  • Merck defeated in antibiotic patent case in US Merck defeated in antibiotic patent case in US

    Merck defeated in antibiotic patent case in US. Loses four patents protecting Cubicin from generic competition. ... Cubicin is an injectable antibiotic indicated for complicated skin and skin structure infections caused by Gram-positive bacteria, as well

  • CHMP October meeting gives recommendations for Pfizer and MSD CHMP October meeting gives recommendations for Pfizer and MSD

    Novartis' Cubicin (daptomycin) was backed for use in adults and paediatric patients with complicated skin and soft-tissue infections.

  • Merck hopes for another Keytruda with new immunotherapy deal Merck hopes for another Keytruda with new immunotherapy deal

    Merck also said it expects to see an increase in overall revenue from its recent $8.4bn purchase of Cubist Pharmaceuticals, the maker of blockbuster antibiotic Cubicin, which made $480m.

  • FDA backs Cubist's antibiotic Zerbaxa FDA backs Cubist's antibiotic Zerbaxa

    The approval of Zerbaxa adds to Cubist's stable of antibiotics, which include $1bn-a-year blockbuster Cubicin (daptomycin) as well as recently-approved Sivextro (tedizolid phosphate) for acute bacterial skin ... The ruling opened the door for generic

  • UPDATE: Merck to acquire Cubist for $8.4bn UPDATE: Merck to acquire Cubist for $8.4bn

    Its main product is currently Cubicin (daptomycin for injection), which is approved for complicated skin and skin structure infections caused by certain bacteria and in Staphylococcus aureus infections of the bloodstream. ... According to the company's

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Cubist: Meeting the challenge in antibiotics Cubist: Meeting the challenge in antibiotics

    Cubicin (daptomycin) is Cubist's leading product with net revenues of $256.7m for the third quarter of 2014.

  • Pharma deals during December 2014 Pharma deals during December 2014

    Cubicin is also approved for the treatment of bacteraemia caused by MRSA and methicillin-susceptible Staphylococcus aureus (MSSA). ... Under this ruling, four out of five Cubist patents protecting Cubicin were invalidated.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Melinta names chief medical officer Melinta names chief medical officer

    She has prior experience in developing anti-infectives, including Cubicin (daptomycin) during her time at Novartis, where she served as VP and global programme head for the company's immunology and ... Melinta's CEO Mary Szela said: "The extensive

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics